Open
20/20從醫療院所收集大量的臨床癌症腫瘤標記資料，並透過運用先進的技術進行分析。
20/20's innovative business model uses advanced analytics on large volumes of real world,clinically revelent patient health data collected from hospital centers where tumor biomaker testing has been used for many years.
20/20's innovative business model uses advanced analytics on large volumes of real world,clinically revelent patient health data collected from hospital centers where tumor biomaker testing has been used for many years.